Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for cancer cachexia and treatment side effects
jRCT1051220093Recruiting
- Sponsor
- Seihoku Clinic
- Start
- Aug 2022
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in cancer anorexia-cachexia syndrome (CACS) and Adverse effects of anticancer therapy (AEs), sponsored by Seihoku Clinic. Primary endpoints: Common tumor markers, High-sensitive C-reactive protein (hs-CRP) and 7 more. Started Aug 2022; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
cancer anorexia-cachexia syndrome (CACS)Adverse effects of anticancer therapy (AEs)
Beyond the preview
Go deeper on jRCT1051220093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220093.